These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27318396)

  • 21. Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
    Choi E; Ding VY; Luo SJ; Ten Haaf K; Wu JT; Aredo JV; Wilkens LR; Freedman ND; Backhus LM; Leung AN; Meza R; Lui NS; Haiman CA; Park SL; Le Marchand L; Neal JW; Cheng I; Wakelee HA; Tammemägi MC; Han SS
    JAMA Oncol; 2023 Dec; 9(12):1640-1648. PubMed ID: 37883107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems.
    Ritzwoller DP; Meza R; Carroll NM; Blum-Barnett E; Burnett-Hartman AN; Greenlee RT; Honda SA; Neslund-Dudas C; Rendle KA; Vachani A
    JAMA Netw Open; 2021 Oct; 4(10):e2128176. PubMed ID: 34636916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data.
    Williams RM; Li T; Luta G; Wang MQ; Adams-Campbell L; Meza R; Tammemägi MC; Taylor KL
    Cancer; 2022 May; 128(9):1812-1819. PubMed ID: 35201610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do Lung Cancer Eligibility Criteria Align with Risk among Blacks and Hispanics?
    Fiscella K; Winters P; Farah S; Sanders M; Mohile SG
    PLoS One; 2015; 10(11):e0143789. PubMed ID: 26618478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the characteristics of the population eligible for lung cancer screening under 2013 and population newly eligible under 2021 US Preventive Services Task Force recommendations.
    Yell N; Eberth JM; Alberg AJ; Hung P; Schootman M; McLain AC; Munden RF
    Cancer Causes Control; 2024 Sep; 35(9):1233-1243. PubMed ID: 38717723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voluntary lung function screening to reveal new COPD cases in southern Italy.
    Capozzolo A; Castellana G; Dragonieri S; Carratù P; Liotino V; Vulpi MR; Marra L; Resta E; Intiglietta P; Resta O
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2035-2042. PubMed ID: 28744118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis.
    Lowry KP; Gazelle GS; Gilmore ME; Johanson C; Munshi V; Choi SE; Tramontano AC; Kong CY; McMahon PM
    Cancer; 2015 May; 121(10):1556-62. PubMed ID: 25652107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proportion of Non-Small-Cell Lung Cancer Patients that Would Have Been Eligible for Lung Cancer Screening.
    Wu GX; Goldstein L; Kim JY; Raz DJ
    Clin Lung Cancer; 2016 Sep; 17(5):e131-e139. PubMed ID: 26872765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disparities of National Lung Cancer Screening Guidelines in the US Population.
    Han SS; Chow E; Ten Haaf K; Toumazis I; Cao P; Bastani M; Tammemagi M; Jeon J; Feuer EJ; Meza R; Plevritis SK
    J Natl Cancer Inst; 2020 Nov; 112(11):1136-1142. PubMed ID: 32040195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of lung cancer risk model (PLCO
    Lebrett MB; Balata H; Evison M; Colligan D; Duerden R; Elton P; Greaves M; Howells J; Irion K; Karunaratne D; Lyons J; Mellor S; Myerscough A; Newton T; Sharman A; Smith E; Taylor B; Taylor S; Walsham A; Whittaker J; Barber PV; Tonge J; Robbins HA; Booton R; Crosbie PAJ
    Thorax; 2020 Aug; 75(8):661-668. PubMed ID: 32631933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lung Cancer Screening in Brazil Comparing the 2013 and 2021 USPSTF Guidelines.
    Emmerick ICM; Campos MR; Castanheira D; Muzy J; Marques A; Arueira Chaves L; Sobreira da Silva MJ
    JAMA Netw Open; 2023 Dec; 6(12):e2346994. PubMed ID: 38079172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening.
    Howard DH; Richards TB; Bach PB; Kegler MC; Berg CJ
    Cancer; 2015 Dec; 121(24):4341-7. PubMed ID: 26372542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
    Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should we be screening for COPD? - looking through the lens of lung cancer screening.
    Young RP; Scott RJ
    Expert Rev Respir Med; 2023; 17(9):753-771. PubMed ID: 37728077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating efficacy of current lung cancer screening guidelines.
    Nemesure B; Plank A; Reagan L; Albano D; Reiter M; Bilfinger TV
    J Med Screen; 2017 Dec; 24(4):208-213. PubMed ID: 28201949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening.
    Smeltzer MP; Liao W; Faris NR; Fehnel C; Goss J; Shepherd CJ; Ramos R; Qureshi T; Mukhopadhyay A; Ray MA; Osarogiagbon RU
    J Thorac Oncol; 2023 Feb; 18(2):158-168. PubMed ID: 36208717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of risk prediction models to select lung cancer screening participants in Europe: a prospective cohort consortium analysis.
    Feng X; Goodley P; Alcala K; Guida F; Kaaks R; Vermeulen R; Downward GS; Bonet C; Colorado-Yohar SM; Albanes D; Weinstein SJ; Goldberg M; Zins M; Relton C; Langhammer A; Skogholt AH; Johansson M; Robbins HA
    Lancet Digit Health; 2024 Sep; 6(9):e614-e624. PubMed ID: 39179310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-Based lung cancer screening: A systematic review.
    Toumazis I; Bastani M; Han SS; Plevritis SK
    Lung Cancer; 2020 Sep; 147():154-186. PubMed ID: 32721652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When to reinvite initially ineligible populations for targeted lung cancer screening?
    Goodley P; Crosbie PAJ; Sperrin M; Merchant Z; Booton R; Balata H
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38754907
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.